LATEST
EQT agreed to acquire CleanawaynewNavigator Gas / Navigator HoldingsAlcoa / AliGroupInternational Seaways agreed to acquire BrutonBoston Crest PVT / LQR HouseBrady acquired Productivity Solutions and Services businessJMSB / EFSIVista Equity Partners / PKI Business UnitBluegem Capital Partners / Rispo GroupApax Partners agreed to acquire OdidoGTCR agreed to acquire CCC Intelligent SolutionsEQT agreed to acquire Stockbridge
Open App
ClosedPublished 1 Jul 2025

TuHURA Biosciences, Inc. /
Kineta, Inc.

TuHURA Biosciences completes Kineta acquisition, adding a cancer drug candidate

Buy side: TuHURA Biosciences, Inc.
Buy sideTuHURA Biosciences, Inc.
Target: Kineta, Inc.
TargetKineta, Inc.
Source · 1 Jul 2025Source-verified
See the source
Buy side: TuHURA Biosciences, Inc.
Buy sideTuHURA Biosciences, Inc.
Target: Kineta, Inc.
TargetKineta, Inc.
01 / BuyerTuHURA Biosciences, Inc.
02 / TargetKineta, Inc.
Source-verified
01

What happened

TuHURA Biosciences, Inc. completed its acquisition of Kineta, Inc. Kineta’s VISTA inhibiting mAb, now named TBS-2025, is a Phase 2 ready drug candidate.

Kineta shareholders received TuHURA common stock, with additional shares and potential cash consideration tied to disposed asset payments.

02

The source

Everything on this page comes from the source below.

01
Source · Original source

TuHURA Biosciences completes Kineta acquisition, adding a cancer drug candidate

This document is the source for the companies, stage and people on this page.

Source-verified
03

Timeline

Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.

  1. Published by the source

    The source this page is built from.

    Source-verified

The same firms, in other deals

The firms' deal history and connections across other deals.

These firms' full profiles are part of Pro.

Request an inviteAlready invited? Sign in

Carrywatch Pro is by invitation. An invite lets you buy Pro.